Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses

Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses

The approval of the first oncolytic virus for the treatment of metastatic melanoma and the compiling evidence that the use of oncolytic viruses can enhance cancer immunotherapies targeted against various immune checkpoint proteins has attracted great interest in the field of cancer virotherapy. We h...

Cur síos iomlán

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Erkko Ylösmäki, Cristina Malorzo, Cristian Capasso, Oona Honkasalo, Manlio Fusciello, Beatriz Martins, Leena Ylösmäki, Antti Louna, Sara Feola, Henrik Paavilainen, Karita Peltonen, Veijo Hukkanen, Tapani Viitala, Vincenzo Cerullo
Formáid:	Artigo
Teanga:	Béarla
Foilsithe / Cruthaithe:	2018
Rochtain ar líne:	https://doi.org/10.1016/j.ymthe.2018.06.008
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses
de réir: Ylösmäki, Erkko, et al.
Foilsithe / Cruthaithe: (2018)

Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors
de réir: Sara Feola, et al.
Foilsithe / Cruthaithe: (2018)

Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin
de réir: Ylösmäki, Erkko, et al.
Foilsithe / Cruthaithe: (2021)

Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy
de réir: Ylösmäki, Leena, et al.
Foilsithe / Cruthaithe: (2019)

Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform
de réir: Ylösmäki, Erkko, et al.
Foilsithe / Cruthaithe: (2021)

Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform
de réir: Erkko Ylösmäki, et al.
Foilsithe / Cruthaithe: (2021)

Design and application of oncolytic viruses for cancer immunotherapy
de réir: Erkko Ylösmäki, et al.
Foilsithe / Cruthaithe: (2019)

Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment
de réir: Sara Feola, et al.
Foilsithe / Cruthaithe: (2021)

A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella
de réir: Fusciello, Manlio, et al.
Foilsithe / Cruthaithe: (2022)

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines
de réir: Feola, Sara, et al.
Foilsithe / Cruthaithe: (2022)

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines
de réir: Sara Feola, et al.
Foilsithe / Cruthaithe: (2022)

Artificially cloaked viral nanovaccine for cancer immunotherapy
de réir: Fusciello, Manlio, et al.
Foilsithe / Cruthaithe: (2019)

Artificially cloaked viral nanovaccine for cancer immunotherapy
de réir: Manlio Fusciello, et al.
Foilsithe / Cruthaithe: (2019)

Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors
de réir: Feola, S., et al.
Foilsithe / Cruthaithe: (2018)

Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine
de réir: Feola, Sara, et al.
Foilsithe / Cruthaithe: (2022)

GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses
de réir: Hamdan, Firas, et al.
Foilsithe / Cruthaithe: (2021)

Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma
de réir: Jacopo Chiaro, et al.
Foilsithe / Cruthaithe: (2021)

Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy
de réir: Peltonen, Karita, et al.
Foilsithe / Cruthaithe: (2021)

Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma
de réir: Chiaro, Jacopo, et al.
Foilsithe / Cruthaithe: (2021)

Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
de réir: Hamdan, Firas, et al.
Foilsithe / Cruthaithe: (2021)

Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site
de réir: Lopes, Alessandra, et al.
Foilsithe / Cruthaithe: (2019)

PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification
de réir: Feola, Sara, et al.
Foilsithe / Cruthaithe: (2021)

Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
de réir: Firas Hamdan, et al.
Foilsithe / Cruthaithe: (2021)

Attenuation of Semliki Forest Virus Neurovirulence by MicroRNA-Mediated Detargeting
de réir: Ylösmäki, Erkko, et al.
Foilsithe / Cruthaithe: (2013)

Attenuation of Semliki Forest Virus Neurovirulence by MicroRNA-Mediated Detargeting
de réir: Erkko Ylösmäki, et al.
Foilsithe / Cruthaithe: (2012)

MicroRNA-Mediated Suppression of Oncolytic Adenovirus Replication in Human Liver
de réir: Ylösmäki, Erkko, et al.
Foilsithe / Cruthaithe: (2013)

Enzymatic Properties and Intracellular Localization of the Novel Trichoderma reesei β-Glucosidase BGLII (Cel1A)
de réir: Saloheimo, Markku, et al.
Foilsithe / Cruthaithe: (2002)

Generation of a Conditionally Replicating Adenovirus Based on Targeted Destruction of E1A mRNA by a Cell Type-Specific MicroRNA
de réir: Ylösmäki, Erkko, et al.
Foilsithe / Cruthaithe: (2008)

Enzymatic Properties and Intracellular Localization of the Novel <i>Trichoderma reesei</i> β-Glucosidase BGLII (Cel1A)
de réir: Markku Saloheimo, et al.
Foilsithe / Cruthaithe: (2002)

Generation of a Conditionally Replicating Adenovirus Based on Targeted Destruction of E1A mRNA by a Cell Type-Specific MicroRNA
de réir: Erkko Ylösmäki, et al.
Foilsithe / Cruthaithe: (2008)

The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1
de réir: Kalke, Kiira, et al.
Foilsithe / Cruthaithe: (2022)

Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma
de réir: Capasso, Cristian, et al.
Foilsithe / Cruthaithe: (2015)

Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma
de réir: Cristian Capasso, et al.
Foilsithe / Cruthaithe: (2015)

A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma
de réir: Capasso, Cristian, et al.
Foilsithe / Cruthaithe: (2017)

Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor
de réir: Flavia Fontana, et al.
Foilsithe / Cruthaithe: (2019)

Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor
de réir: Fontana, Flavia, et al.
Foilsithe / Cruthaithe: (2019)

Nuclear Translocation of Crk Adaptor Proteins by the Influenza A Virus NS1 Protein
de réir: Ylösmäki, Leena, et al.
Foilsithe / Cruthaithe: (2016)

Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors
de réir: Sara Feola, et al.
Foilsithe / Cruthaithe: (2024)

Extracellular vesicles provide a capsid-free vector for oncolytic adenoviral DNA delivery
de réir: Saari, Heikki, et al.
Foilsithe / Cruthaithe: (2020)

Extracellular vesicles provide a capsid‐free vector for oncolytic adenoviral DNA delivery
de réir: H Saari, et al.
Foilsithe / Cruthaithe: (2020)